Quantcast
Last updated on April 18, 2014 at 10:08 EDT

Latest Daiichi Sankyo Inc. Stories

2014-04-18 08:22:04

PARSIPPANY, N.J., April 18, 2014 /PRNewswire/ -- Daiichi Sankyo, Inc. announced today that Ken Keller will join the company as President of its Commercial operations in the United States starting May 1, 2014. In his role, Mr. Keller will be responsible for leading marketing, sales, medical affairs and supply chain operations for Daiichi Sankyo in the U.S. "We are very pleased to welcome Ken Keller into the Daiichi Sankyo family," said Joji Nakayama, President and CEO of Daiichi...

2013-11-19 12:30:10

- Once-daily edoxaban, evaluated in two treatment arms (60 mg and 30 mg), achieved the primary endpoint of non-inferior efficacy versus warfarin in the prevention of stroke or systemic embolism DALLAS and TOKYO, Nov. 19, 2013 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced results today from the phase 3 ENGAGE AF-TIMI 48 study.(1) This clinical trial found that the investigational, oral, once-daily direct factor Xa-inhibitor edoxaban met...

2013-10-03 16:23:23

PARSIPPANY, N.J., Oct. 3, 2013 /PRNewswire/ -- Daiichi Sankyo, Inc. today announced that Glenn Gormley, MD, PhD, has been named corporate President and Chairman of Daiichi Sankyo, Inc. Dr. Gormley will also continue in his existing roles as President, Daiichi Sankyo Pharma Development, Global Head of Research and Development and Senior Executive Officer of Daiichi Sankyo, Co. Ltd. In addition, Greg Barrett has been appointed as the new acting head of the Commercial Division of...

2013-06-06 08:29:40

PARSIPPANY, N.J., June 6, 2013 /PRNewswire/ -- Recent guidance from the American Association of Clinical Endocrinologists (AACE) highlight for the first time a cardiovascular risk factor management algorithm that identifies treatments of dyslipidemia in patients with type 2 diabetes.(1 )In these new guidelines, Welchol(®) (colesevelam HCI) is the only therapy recognized that provides patients with a dual-benefit: it helps to lower both A1C and LDL cholesterol ("bad" cholesterol or LDL-C)...

2013-04-25 08:34:05

Daiichi Sankyo to support and co-sponsor phase 1 Clinical Study MOUNT KISCO, New York, USA, and Tokyo, Japan, April 25, 2013 /PRNewswire/ -- Perosphere Inc. and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that they have entered into a clinical trial agreement under which Daiichi Sankyo will support and co-sponsor a phase 1 clinical study testing the safety, tolerability and effectiveness of PER977 to reverse the anticoagulant activity of edoxaban,...

2013-04-09 16:23:54

Acsis turnkey solution will help meet California mandate and federal regulations MARLTON, N.J., April 9, 2013 /PRNewswire/ -- Acsis Inc., the market leader for Enterprise Serialization solutions, today announced Daiichi Sankyo, Inc. selected the Acsis Serialization Management Suite to comply with FDA e-pedigree mandates and other federal regulations. The turnkey solution includes the Acsis proven serialization management solution with best-of-breed vision and printing equipment from...

2012-10-25 07:30:51

TOKYO, Oct. 25, 2012 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has completed patient enrolment in the global Hokusai-VTE phase 3 study investigating the once-daily oral factor Xa inhibitor edoxaban for the treatment and prevention of recurrence of venous thromboembolism (VTE) in patients who have had an acute symptomatic deep vein thrombosis (DVT), pulmonary embolism (PE), or both.(1,2 ) Hokusai-VTE is the largest single phase 3...

2012-10-23 11:25:53

MIAMI, Oct. 23, 2012 /PRNewswire/ -- Daiichi Sankyo, Inc. and Eli Lilly and Company (NYSE: LLY) today announced new results of two retrospective, observational, comparative effectiveness studies of U.S. hospital data comparing rates of readmission for subsequent heart attack and initial hospitalization costs among patients with acute coronary syndromes (ACS) treated with a percutaneous coronary intervention (PCI) and antiplatelet therapy, including Effient(®) (prasugrel) or...

2012-10-09 07:28:02

PRINCETON, N.J., Oct. 9, 2012 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), has launched the authorized generic cevimeline hydrochloride 30 mg. capsules in the U.S. market, under an agreement with Daiichi Sankyo, Inc. Cevimeline hydrochloride is indicated for the treatment of symptoms of dry mouth associated with Sjogren's syndrome, an autoimmune disorder affecting the moisture-producing glands, and is presently...

2012-08-25 22:20:14

INDIANAPOLIS and TOKYO, Aug. 26, 2012 /PRNewswire/ -- Daiichi Sankyo Company, Limited (TSE: 4568) and Eli Lilly and Company (NYSE: LLY) today announced data from the TRILOGY ACS study, a phase III trial comparing prasugrel plus aspirin to clopidogrel plus aspirin in patients with unstable angina (UA) or non-ST elevation myocardial infarction (NSTEMI), who were managed medically without an artery-opening procedure. At 30 months, 13.9 percent of prasugrel patients vs. 16.0 percent of...